GlassScriptPhysician profile
William Lee Gibson
NPI 1205047578
$13,130.72
in general payments reported to CMS, 2019-2025
51 companies · $2,673 in 2025
The $2,673 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $591 · 2021: $1,927 · 2022: $2,206 · 2023: $2,675 · 2024: $2,574 · 2025: $2,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,923.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,324.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,090.13 | 2020-2025 | |
| Amgen INC. | $1,007.11 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $850.96 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $832.06 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $772.70 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $740.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $585.12 | 2020-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $493.73 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.12 | 2023-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $442.52 | 2023-2025 | |
| Pfizer INC. | $353.07 | 2019-2025 | |
| Ardelyx, INC. | $332.56 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $304.72 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sanofi-Aventis U.S. LLC | $294.23 | 2019-2023 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $283.48 | 2021-2022 | |
| Amarin Pharma, INC. | $256.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.31 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $177.81 | 2021-2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $164.03 | 2022 | |
| Astellas Pharma US INC | $156.34 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $155.85 | 2024-2025 | Auvelity |
| Viatris Specialty LLC | $146.79 | 2025 | Yupelri |
| Mylan Specialty L.P. | $140.16 | 2021-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $139.27 | 2020-2021 | |
| Lundbeck LLC | $132.49 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $126.69 | 2023-2025 | Epclusa |
| Alkermes, INC. | $125.79 | 2023-2024 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $110.29 | 2020-2023 | |
| Insulet Corporation | $107.50 | 2019-2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $96.52 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $87.90 | 2021-2024 | |
| Dexcom, INC. | $80.65 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $80.64 | 2024 | |
| Merck Sharp & Dohme LLC | $80.39 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $43.58 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $40.57 | 2024-2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $32.27 | 2019 | |
| Daiichi Sankyo INC. | $28.38 | 2025 | Injectafer |
| Atland Pharmaceuticals, LLC | $27.12 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Eisai INC. | $20.71 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.48 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $19.61 | 2023 | Quviviq |
| Corcept Therapeutics | $18.15 | 2019 | |
| Smith+Nephew, INC. | $17.72 | 2023 | Grafix Pl |
| Ucb, INC. | $17.19 | 2024 | Briviact |
| E.R. Squibb & Sons, L.L.C. | $16.89 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $16.25 | 2025 | Qelbree |
| Aytu Biopharma, INC. | $14.26 | 2020 | |
| Indivior INC. | $14.12 | 2021 | |
| Allergan, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.